Mylan NV (MYL)

17.70
NASDAQ : Health Technology
Prev Close 17.26
Day Low/High 17.25 / 17.83
52 Wk Low/High 16.63 / 35.45
Avg Volume 5.85M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 8.91B
EPS 0.70
P/E Ratio 191.78
Div & Yield N.A. (N.A)

Latest News

Pfizer's Long-Term Outlook Is Murky, Says UBS on Lowering Price Target

Pfizer's Long-Term Outlook Is Murky, Says UBS on Lowering Price Target

UBS lowers its price target on Pfizer to $37 a share and maintains its neutral rating on the stock.

Mylan Beats Earnings Estimates With Shares in Recovery Mode

Mylan Beats Earnings Estimates With Shares in Recovery Mode

Buy Mylan at the market and add to positions on weakness to its monthly value level at $15.75. The weekly chart will be positive on a weekly close above its five-week modified moving average at $19.43.

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

Mylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates Forecast

The company generates increased sales from its existing suite of generic drugs as well as some new product launches.

Mylan Doles Out the Right Prescription for Investors

Mylan Doles Out the Right Prescription for Investors

Strong demand for its lineup of generic drugs and more to come from additional upcoming launches as it moves toward closing its deal with Pfizer's PFE Upjohn business all helped boost third-quarter sales and earnings for Mylan.

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon

Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.

Mylan Reports Third Quarter 2019 Results And Updates 2019 Guidance

Mylan Reports Third Quarter 2019 Results And Updates 2019 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2019 /PRNewswire/ --  Mylan N.

Dow Futures, Uber, Shake Shack and China Trade - 5 Things You Must Know Tuesday

Dow Futures, Uber, Shake Shack and China Trade - 5 Things You Must Know Tuesday

U.S. stock futures rise a day after the three major U.S. benchmark indexes posted record closing highs on positive trade developments between the U.S. and China and strong corporate earnings; Uber posts $1.2 billion loss but sees profitability in 2021; Shake Shacks sinks on a weak same-store sales forecast.

The Week Ahead: Earnings Season Is Far From Over

The Week Ahead: Earnings Season Is Far From Over

Disney, Qualcomm and Square are among 75 key reports we are watching.

Mylan To Release Third Quarter 2019 Financial Results On Nov. 5, 2019

Mylan To Release Third Quarter 2019 Financial Results On Nov. 5, 2019

HERTFORDSHIRE, England and PITTSBURGH, Oct. 24, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Theravance Biopharma And Mylan To Present New Data On YUPELRI® (revefenacin) At The 2019 CHEST Annual Meeting

Theravance Biopharma And Mylan To Present New Data On YUPELRI® (revefenacin) At The 2019 CHEST Annual Meeting

Study provides data on YUPELRI when administered with formoterol in patients with COPD

Mylan to Pay $30M to Settle SEC Lawsuit Related to EpiPen Misclassification

Mylan to Pay $30M to Settle SEC Lawsuit Related to EpiPen Misclassification

Mylan called the settlement "the right course of action."

Mylan Finalizes Previously Disclosed Settlement With U.S. Securities And Exchange Commission

Mylan Finalizes Previously Disclosed Settlement With U.S. Securities And Exchange Commission

HERTFORDSHIRE, England, and PITTSBURGH, Sept. 27, 2019 /PRNewswire/ -- Mylan N.

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.

Jim Cramer: Here's Why the Market's So Feckless and Reactive

Jim Cramer: Here's Why the Market's So Feckless and Reactive

So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.

Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex® Injection, A Treatment For Advanced Breast Cancer

Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex® Injection, A Treatment For Advanced Breast Cancer

HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ --  Mylan N.

Hear Now the News (and Updates) on 2 Key Positions

Antares Pharma and Encana are on our radar today.

Teva's Generic EpiPen Jr Is Now Available for $300

Teva's Generic EpiPen Jr Is Now Available for $300

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLX, CRMD, DHX, FTAI, HCP, MHO, MRC, XPO Downgrades: AINC, ARW, BPY, CRAY, EARN, FLR, HRTG, IDSY, MYL, PATK, PXLW, TRQ, TWI, WMS Initiations: BCDA, USX Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.

Two Pharmaceutical Stocks That Jim Cramer's Watching

Two Pharmaceutical Stocks That Jim Cramer's Watching

Jim Cramer's eyeing Merck and Pfizer. Here's why.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Pfizer to Combine Off-Patent Drug Division With Mylan

Pfizer to Combine Off-Patent Drug Division With Mylan

Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

TheStreet Quant Rating: D+ (Sell)